EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

Biotechnology

Healthcare
$2.99 +1.98%

+$0.26 today

Market cap
$250.69M
Beta
1.75
P/E (TTM)
-4.2
EPS (TTM)
-$3.16
52W Low $7.94High $19.11

Volume 2.75M

Average 0.95M

EYPT Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

EyePoint Pharmaceuticals, Inc.NASDAQ: EYPT

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 24.1%

Gross margin was 24.1% in Q1 FY2026, down 72.6 pp from a year earlier. On a trailing-twelve-month basis it was 76.5%, down 16.8 pp year over year. Over 3 fiscal years it widened by 13.5 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
24.1%-15.4 pp QoQ
Last fiscal yearDec 2025
93.4%+2.0 pp YoY
LTMMar 2026
76.5%-16.8 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-72.6 pp——
1 year+2.0 pp——
3 years+13.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
93.4%
Year-over-year change
+2.0pp

Gross Margin vs competitors

How EYPT compares with its peers on the latest reported figures

  • EYPT's LTM Mar 2026 gross margin of 76.5% is the 5th highest of the 7 companies compared; the peer median is 83.2%.
  • Its year-over-year change of -16.8 pp is the 4th highest of 7, against a peer median of -12.5 pp.
  • Over three fiscal years its change of +13.5 pp compares with a peer median of +225.8 pp.
EYPT Competitors Peer median
Gross Margin for EYPT and competitors
Company Period LTM level YoY 3-year change
TNGXTango Therapeutics, Inc.FY202596.3% -3.7 pp-3.7 pp
KURAKura Oncology, Inc.LTM Mar 202694.7% -5.0 pp—
NRIXNurix Therapeutics, Inc.LTM Aug 202686.5% +249.4 pp+455.2 pp
SEPNSepterna, Inc.LTM Sep 202679.9% -20.1 pp—
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 202676.5% -16.8 pp+13.5 pp
PROKProKidney Corp.LTM Mar 2026-224.4% -324.4 pp—
PRMEPrime Medicine, Inc.LTM Mar 2026-1082.7% -1182.7 pp—
KODKodiak Sciences Inc.FY2025— ——
BCAXBicara Therapeutics Inc. Common StockFY2025— ——
SVRASavara Inc.FY2025— ——
RZLTRezolute, Inc.FY2025— ——
Peer median (excluding EYPT) 83.2%-12.5 pp+225.8 pp

Competitors are the stored peer set for EYPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue36.94M41.4M46.02M43.27M31.37M
Cost of Revenue8.18M8.33M4.63M3.71M2.07M
Gross Profit28.76M33.08M41.39M39.56M29.31M
Gross Margin77.9%79.9%89.9%91.4%93.4%
Research & Development28.5M49.64M64.66M132.93M221.04M
Selling, General & Admin53.08M60.32M51.79M52.49M51.7M
Operating Expenses84.04M132.72M116.45M185.42M272.74M
Depreciation & Amortization2.77M2.45M464K1.54M2.31M
EBITDA(50.15M)(96.62M)(69M)(129.23M)(229.34M)
EBITDA Margin-135.8%-233.4%-149.9%-298.6%-731.1%
Operating Income(55.28M)(99.64M)(75.07M)(145.85M)(243.43M)
Operating Margin-149.6%-240.6%-163.1%-337.1%-776.0%
Interest Income292K2.13M6.95M15.09M11.75M
Interest Expense5.5M3.19M1.25M14K(33K)
Other Income / Expenses(3.14M)(2.62M)4.36M15.07M11.75M
Income Before Tax(58.42M)(102.25M)(70.71M)(130.78M)(231.68M)
Pre-Tax Margin-158.1%-247.0%-153.7%-302.2%-738.5%
Income Tax Expense0083K90K279K
Net Income(58.42M)(102.25M)(70.8M)(130.87M)(231.96M)
Net Margin-158.1%-247.0%-153.8%-302.4%-739.4%
EPS (Basic)(2.03)(2.74)(1.82)(2.32)(3.17)
EPS (Diluted)(2.03)(2.74)(1.82)(2.32)(3.17)
Weighted Avg Shares28.76M37.32M38.9M56.3M73.25M
Weighted Avg Shares (Diluted)28.76M37.32M38.9M56.3M73.25M

EyePoint Pharmaceuticals, Inc.

NASDAQ:EYPT

Intrinsic Alpha fair value

Locked

Current Price

$2.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.